Gentamicin-mediated ototoxicity and nephrotoxicity: A clinical trial study

Area of Science:

• Pharmacology
• Nephrology
• Ototoxicology

Background:

• Gentamicin, a key aminoglycoside antibiotic, presents administration route controversies due to potential nephrotoxicity and ototoxicity.
• Minimizing adverse effects like deafness and renal insufficiency is crucial for gentamicin therapy.
• This study investigates comparative safety profiles of single versus multiple gentamicin doses.

Purpose of the Study:

• To compare the safety of single-dose versus multiple-dose gentamicin administration.
• To determine the least harmful gentamicin treatment method for sepsis patients.
• To evaluate the impact on renal function and hearing.

Main Methods:

• A clinical study involving 80 sepsis patients (aged 12-55) divided into two groups.
• Group 1 received single-dose gentamicin (5 mg/kg).
• Group 2 received multiple doses (1.7 mg/kg three times daily).

Main Results:

• Single-dose group showed decreased Blood Urea Nitrogen (BUN) and Creatinine (CR) levels, with improved Glomerular Filtration Rate (GFR).
• Multiple-dose group exhibited increased BUN and CR levels, and decreased GFR.
• Audiometric studies revealed a 6.1% hearing problem in the single-dose group versus 12.8% in the multiple-dose group.

Conclusions:

• Single-dose gentamicin administration significantly minimizes nephrotoxicity and ototoxicity compared to multiple doses.
• This suggests single-dose gentamicin is a safer therapeutic option.
• The findings support optimizing gentamicin dosing strategies to reduce patient harm.